The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2026 | Identifying responders to first-line therapy in advanced HCC
Manon Allaire, MD, Greater Paris University Hospitals, Paris, France, comments on the current challenges in identifying patients with advanced hepatocellular carcinoma (HCC) who would respond best to different first-line treatment combinations, such as immunotherapy or anti-VEGF therapy. The lack of tumor material due to the common use of imaging instead of biopsy in HCC diagnosis has limited the availability of data on predictors of response. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, thank you very much for this question. So here also it’s another really important point because we know that we have some patients at higher risk of developing HCC and so now we can propose to them like a surveillance strategy with ultrasound and blood tests and so on. However, right now we are facing a new, let’s say, population of patients. I’m thinking of the patients with metabolic disease because for some of them, they will present liver cancer without cirrhosis...
Yes, thank you very much for this question. So here also it’s another really important point because we know that we have some patients at higher risk of developing HCC and so now we can propose to them like a surveillance strategy with ultrasound and blood tests and so on. However, right now we are facing a new, let’s say, population of patients. I’m thinking of the patients with metabolic disease because for some of them, they will present liver cancer without cirrhosis. And so these patients, for example, they are not really included in the surveillance program. And indeed, for them, we need to work on identifying predictors for early detection for HCC. And unfortunately, for the moment, we don’t have so many tools for this. You have data regarding combining different blood test approaches, combining with clinical data such as the age and the sex also. But unfortunately, for the moment, we don’t have so many things. A big area of research right now is also to study, you know, blood markers, blood predictors, such as also tumoral ctDNA, and so on. But for the moment, for HCC, here also, we don’t have so many data, but this is something we really need to work on, especially as we are seeing more and more patients with HCC, for example, and without cirrhosis in the setting of metabolic disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
